Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$122.92
-3.48-2.75%
At close: -
$122.92
0.000.00%
After Hours: Mar 28, 4:00 PM EDT
Comments
Loading...
Jazz Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:JAZZ | Benzinga
Jazz Pharmaceuticals PLC has a consensus price target of $192.65 based on the ratings of 21 analysts. The high is $230 issued by Truist Securities on March 6, 2025. The low is $150 issued by Cantor Fitzgerald on February 26, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Morgan Stanley, and UBS on March 10, 2025, March 7, 2025, and March 7, 2025, respectively. With an average price target of $193 between HC Wainwright & Co., Morgan Stanley, and UBS, there's an implied 57.01% upside for Jazz Pharmaceuticals PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Morgan Stanley
UBS
Truist Securities
Needham
1calculated from analyst ratings
Analyst Ratings for Jazz Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/10/2025 | Buy Now | 76.54% | HC Wainwright & Co. | Oren Livnat60% | $200 → $217 | Maintains | Buy | Get Alert |
| 03/07/2025 | Buy Now | 48.88% | Morgan Stanley | Jeffrey Hung55% | $175 → $183 | Assumes | → Overweight | Get Alert |
| 03/07/2025 | Buy Now | 45.62% | UBS | Ashwani Verma47% | $145 → $179 | Upgrade | Neutral → Buy | Get Alert |
| 03/06/2025 | Buy Now | 87.11% | Truist Securities | Gregory Fraser64% | $220 → $230 | Maintains | Buy | Get Alert |
| 03/05/2025 | Buy Now | 70.84% | Needham | Ami Fadia61% | $210 → $210 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 62.71% | Barclays | Balaji Prasad54% | $190 → $200 | Maintains | Overweight | Get Alert |
| 02/26/2025 | Buy Now | 22.03% | Cantor Fitzgerald | Charles Duncan72% | $140 → $150 | Downgrade | Overweight → Neutral | Get Alert |
| 02/26/2025 | Buy Now | 43.18% | Piper Sandler | David Amsellem71% | $163 → $176 | Reiterates | Overweight → Overweight | Get Alert |
| 02/26/2025 | Buy Now | 44.81% | RBC Capital | Gregory Renza47% | $179 → $178 | Maintains | Outperform | Get Alert |
| 02/26/2025 | Buy Now | 70.03% | JP Morgan | Jessica Fye67% | $200 → $209 | Maintains | Overweight | Get Alert |
| 02/26/2025 | Buy Now | 70.84% | Needham | Ami Fadia61% | $205 → $210 | Maintains | Buy | Get Alert |
| 02/13/2025 | Buy Now | 38.3% | Wells Fargo | Mohit Bansal72% | $130 → $170 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 12/12/2024 | Buy Now | 32.61% | Piper Sandler | David Amsellem71% | $163 → $163 | Reiterates | Overweight → Overweight | Get Alert |
| 12/12/2024 | Buy Now | 45.62% | RBC Capital | Gregory Renza47% | $179 → $179 | Reiterates | Outperform → Outperform | Get Alert |
| 12/12/2024 | Buy Now | 68.4% | Needham | Ami Fadia61% | $207 → $207 | Reiterates | Buy → Buy | Get Alert |
| 12/10/2024 | Buy Now | 45.62% | RBC Capital | Gregory Renza47% | $179 → $179 | Reiterates | Outperform → Outperform | Get Alert |
| 11/22/2024 | Buy Now | 62.71% | HC Wainwright & Co. | Oren Livnat60% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 11/21/2024 | Buy Now | 68.4% | Needham | Ami Fadia61% | $207 → $207 | Reiterates | Buy → Buy | Get Alert |
| 11/21/2024 | Buy Now | 32.61% | Piper Sandler | David Amsellem71% | $166 → $163 | Reiterates | Overweight → Overweight | Get Alert |
| 11/18/2024 | Buy Now | 31.79% | Baird | Joel Beatty69% | $154 → $162 | Maintains | Outperform | Get Alert |
| 11/07/2024 | Buy Now | 58.64% | TD Cowen | — | $200 → $195 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | 68.4% | Needham | Ami Fadia61% | $207 → $207 | Reiterates | Buy → Buy | Get Alert |
| 10/23/2024 | Buy Now | 45.62% | RBC Capital | Gregory Renza47% | $175 → $179 | Maintains | Outperform | Get Alert |
| 10/04/2024 | Buy Now | 42.37% | RBC Capital | Gregory Renza47% | $174 → $175 | Maintains | Outperform | Get Alert |
| 09/10/2024 | Buy Now | 66.78% | Needham | Ami Fadia61% | $205 → $205 | Reiterates | Buy → Buy | Get Alert |
| 09/09/2024 | Buy Now | 13.9% | Cantor Fitzgerald | Charles Duncan72% | $140 → $140 | Reiterates | Overweight → Overweight | Get Alert |
| 08/19/2024 | Buy Now | 64.33% | JP Morgan | Jessica Fye67% | $190 → $202 | Maintains | Overweight | Get Alert |
| 08/01/2024 | Buy Now | 13.9% | Cantor Fitzgerald | Charles Duncan72% | $140 → $140 | Reiterates | Overweight → Overweight | Get Alert |
| 08/01/2024 | Buy Now | 35.05% | Piper Sandler | David Amsellem71% | $188 → $166 | Maintains | Overweight | Get Alert |
| 08/01/2024 | Buy Now | 41.56% | RBC Capital | Gregory Renza47% | $175 → $174 | Maintains | Outperform | Get Alert |
| 08/01/2024 | Buy Now | -2.38% | Wells Fargo | Mohit Bansal72% | $140 → $120 | Maintains | Equal-Weight | Get Alert |
| 08/01/2024 | Buy Now | 66.78% | Needham | Ami Fadia61% | $208 → $205 | Maintains | Buy | Get Alert |
| 08/01/2024 | Buy Now | 62.71% | HC Wainwright & Co. | Oren Livnat60% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2024 | Buy Now | 25.28% | Baird | Joel Beatty69% | $160 → $154 | Maintains | Outperform | Get Alert |
| 07/12/2024 | Buy Now | 22.03% | Morgan Stanley | Jeffrey Hung55% | $160 → $150 | Maintains | Equal-Weight | Get Alert |
| 07/02/2024 | Buy Now | -8.07% | UBS | Ashwani Verma47% | $117 → $113 | Maintains | Neutral | Get Alert |
| 06/20/2024 | Buy Now | 70.84% | Needham | Ami Fadia61% | $222 → $210 | Maintains | Buy | Get Alert |
| 06/05/2024 | Buy Now | 37.49% | Goldman Sachs | Madhu Kumar72% | → $169 | Initiates | → Buy | Get Alert |
| 05/03/2024 | Buy Now | 62.71% | HC Wainwright & Co. | Oren Livnat60% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2024 | Buy Now | 62.71% | Barclays | Balaji Prasad54% | $230 → $200 | Maintains | Overweight | Get Alert |
| 05/02/2024 | Buy Now | 80.61% | Needham | Ami Fadia61% | $222 → $222 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | 46.44% | Cantor Fitzgerald | Charles Duncan72% | $180 → $180 | Reiterates | Overweight → Overweight | Get Alert |
| 03/22/2024 | Buy Now | 46.44% | Cantor Fitzgerald | Charles Duncan72% | $180 → $180 | Reiterates | Overweight → Overweight | Get Alert |
| 03/22/2024 | Buy Now | 54.57% | JP Morgan | Jessica Fye67% | $170 → $190 | Maintains | Overweight | Get Alert |
| 03/20/2024 | Buy Now | 78.98% | Needham | Ami Fadia61% | $220 → $220 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2024 | Buy Now | 62.71% | Truist Securities | Joon Lee77% | → $200 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2024 | Buy Now | 52.95% | Piper Sandler | David Amsellem71% | $171 → $188 | Reiterates | Overweight → Overweight | Get Alert |
| 03/15/2024 | Buy Now | 87.11% | Stifel | Annabel Samimy67% | $225 → $230 | Maintains | Buy | Get Alert |
| 03/14/2024 | Buy Now | 62.71% | HC Wainwright & Co. | Oren Livnat60% | $204 → $200 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | 87.11% | Barclays | Balaji Prasad54% | $235 → $230 | Maintains | Overweight | Get Alert |
| 03/01/2024 | Buy Now | 6.57% | UBS | Ashwani Verma47% | $135 → $131 | Maintains | Neutral | Get Alert |
| 02/29/2024 | Buy Now | 58.64% | RBC Capital | Gregory Renza47% | $195 → $195 | Reiterates | Outperform → Outperform | Get Alert |
| 02/29/2024 | Buy Now | 46.44% | Cantor Fitzgerald | Charles Duncan72% | $180 → $180 | Reiterates | Overweight → Overweight | Get Alert |
| 02/29/2024 | Buy Now | 38.3% | JP Morgan | Jessica Fye67% | $180 → $170 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 78.98% | Needham | Ami Fadia61% | $225 → $220 | Maintains | Buy | Get Alert |
| 01/29/2024 | Buy Now | 91.18% | Barclays | Balaji Prasad54% | $240 → $235 | Maintains | Overweight | Get Alert |
| 01/03/2024 | Buy Now | 30.17% | Baird | Joel Beatty69% | → $160 | Initiates | → Outperform | Get Alert |
| 12/04/2023 | Buy Now | 62.71% | Truist Securities | Joon Lee77% | → $200 | Reiterates | Buy → Buy | Get Alert |
| 11/29/2023 | Buy Now | 83.05% | Needham | Ami Fadia61% | → $225 | Reiterates | Buy → Buy | Get Alert |
| 11/27/2023 | Buy Now | 9.83% | UBS | Ashwani Verma47% | $170 → $135 | Downgrade | Buy → Neutral | Get Alert |
| 11/09/2023 | Buy Now | 55.39% | RBC Capital | Gregory Renza47% | $200 → $191 | Maintains | Outperform | Get Alert |
| 11/09/2023 | Buy Now | 83.05% | Needham | Ami Fadia61% | $226 → $225 | Maintains | Buy | Get Alert |
| 09/29/2023 | Buy Now | — | Raymond James | Gary Nachman58% | — | Initiates | → Market Perform | Get Alert |
| 08/22/2023 | Buy Now | 46.44% | Cantor Fitzgerald | Brandon Folkes42% | → $180 | Reiterates | Overweight → Overweight | Get Alert |
| 08/14/2023 | Buy Now | 46.44% | Cantor Fitzgerald | Brandon Folkes42% | $210 → $180 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | 65.96% | HC Wainwright & Co. | Oren Livnat60% | → $204 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 76.54% | B of A Securities | Jason Gerberry62% | $204 → $217 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | 63.52% | RBC Capital | Gregory Renza47% | $203 → $201 | Maintains | Outperform | Get Alert |
| 08/10/2023 | Buy Now | 83.86% | Needham | Ami Fadia61% | → $226 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 83.86% | Needham | Ami Fadia61% | → $226 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 52.13% | Morgan Stanley | Jeffrey Hung55% | $187 → $187 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/05/2023 | Buy Now | 83.86% | Needham | Ami Fadia61% | → $226 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2023 | Buy Now | 83.86% | Needham | Ami Fadia61% | $212 → $226 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 65.96% | HC Wainwright & Co. | Oren Livnat60% | → $204 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 72.47% | Needham | Ami Fadia61% | → $212 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 64.33% | RBC Capital | Gregory Renza47% | $207 → $202 | Maintains | Outperform | Get Alert |
| 05/11/2023 | Buy Now | 72.47% | Needham | Ami Fadia61% | $205 → $212 | Maintains | Buy | Get Alert |
| 03/06/2023 | Buy Now | 65.96% | HC Wainwright & Co. | Oren Livnat60% | → $204 | Reiterates | → Buy | Get Alert |
| 03/03/2023 | Buy Now | 72.47% | Goldman Sachs | Madhu Kumar72% | $190 → $212 | Maintains | Buy | Get Alert |
| 03/02/2023 | Buy Now | 66.78% | Needham | Ami Fadia61% | $210 → $205 | Maintains | Buy | Get Alert |
| 12/09/2022 | Buy Now | 54.57% | Goldman Sachs | Madhu Kumar72% | $192 → $190 | Upgrade | Neutral → Buy | Get Alert |
| 11/10/2022 | Buy Now | 56.2% | Goldman Sachs | Madhu Kumar72% | $170 → $192 | Maintains | Neutral | Get Alert |
| 11/10/2022 | Buy Now | 68.4% | RBC Capital | Gregory Renza47% | $206 → $207 | Maintains | Outperform | Get Alert |
| 11/10/2022 | Buy Now | 69.22% | Needham | Ami Fadia61% | $210 → $208 | Maintains | Buy | Get Alert |
| 09/29/2022 | Buy Now | 38.3% | Goldman Sachs | Madhu Kumar72% | $148 → $170 | Maintains | Neutral | Get Alert |
| 09/21/2022 | Buy Now | 20.4% | Goldman Sachs | Madhu Kumar72% | $192 → $148 | Maintains | Neutral | Get Alert |
| 08/04/2022 | Buy Now | 52.95% | BMO Capital | Gary Nachman58% | $185 → $188 | Maintains | Outperform | Get Alert |
| 08/04/2022 | Buy Now | 52.13% | Morgan Stanley | Jeffrey Hung55% | $174 → $187 | Maintains | Equal-Weight | Get Alert |
| 08/04/2022 | Buy Now | 55.39% | UBS | Ashwani Verma47% | $194 → $191 | Maintains | Buy | Get Alert |
| 08/04/2022 | Buy Now | 70.84% | SVB Leerink | Marc Goodman73% | $200 → $210 | Maintains | Outperform | Get Alert |
| 06/14/2022 | Buy Now | 57.83% | UBS | Ashwani Verma47% | → $194 | Initiates | → Buy | Get Alert |
| 05/05/2022 | Buy Now | 69.22% | RBC Capital | Gregory Renza47% | $210 → $208 | Maintains | Outperform | Get Alert |
| 05/05/2022 | Buy Now | 57.01% | Piper Sandler | David Amsellem71% | $197 → $193 | Maintains | Overweight | Get Alert |
| 04/06/2022 | Buy Now | 59.45% | Goldman Sachs | Madhu Kumar72% | $202 → $196 | Downgrade | Buy → Neutral | Get Alert |
FAQ
What is the target price for Jazz Pharmaceuticals (JAZZ) stock?
The latest price target for Jazz Pharmaceuticals (NASDAQ:JAZZ) was reported by HC Wainwright & Co. on March 10, 2025. The analyst firm set a price target for $217.00 expecting JAZZ to rise to within 12 months (a possible 76.54% upside). 42 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Jazz Pharmaceuticals (JAZZ)?
The latest analyst rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) was provided by HC Wainwright & Co., and Jazz Pharmaceuticals maintained their buy rating.
When was the last upgrade for Jazz Pharmaceuticals (JAZZ)?
The last upgrade for Jazz Pharmaceuticals PLC happened on March 7, 2025 when UBS raised their price target to $179. UBS previously had a neutral for Jazz Pharmaceuticals PLC.
When was the last downgrade for Jazz Pharmaceuticals (JAZZ)?
The last downgrade for Jazz Pharmaceuticals PLC happened on February 26, 2025 when Cantor Fitzgerald changed their price target from $140 to $150 for Jazz Pharmaceuticals PLC.
When is the next analyst rating going to be posted or updated for Jazz Pharmaceuticals (JAZZ)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jazz Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jazz Pharmaceuticals was filed on March 10, 2025 so you should expect the next rating to be made available sometime around March 10, 2026.
Is the Analyst Rating Jazz Pharmaceuticals (JAZZ) correct?
While ratings are subjective and will change, the latest Jazz Pharmaceuticals (JAZZ) rating was a maintained with a price target of $200.00 to $217.00. The current price Jazz Pharmaceuticals (JAZZ) is trading at is $122.92, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.